Discontinuation versus continuation of renin-angiotensin system inhibitors in chronic kidney disease stage 3-5 patients: a systematic review and meta-analysis.

ABSTRACT:

Background

Renin-angiotensin system inhibitors (RASi), comprising angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) are known for cardio- and renoprotection. However, there is uncertainty regarding the continuation of ACEi or ARB treatment in patients with chronic kidney disease (CKD) stages 3-5.

Methods

In this meta-analysis, we systematically searched all relevant studies published in PubMed, Embase, and the Cochrane Library up to 30 May 2024. Our objective was to assess the impacts of continuation or discontinuation of RASi in patients with CKD stages 3-5 on all-cause mortality, end-stage kidney disease, major adverse cardiovascular events (MACE), and hyperkalemia. We rated the certainty of the evidence using the Cochrane methods an

SUBMITTER: Chen IW 

PROVIDER: S-EPMC12510950 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature